Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal



Page Path
HOME > Search
5 "Angiotensin II"
Article category
Publication year
Funded articles
Original Article
Basic Research
Article image
Glucagon-Like Peptide Receptor Agonist Inhibits Angiotensin II-Induced Proliferation and Migration in Vascular Smooth Muscle Cells and Ameliorates Phosphate-Induced Vascular Smooth Muscle Cells Calcification
Jinmi Lee, Seok-Woo Hong, Min-Jeong Kim, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
Diabetes Metab J. 2024;48(1):83-96.   Published online January 3, 2024
  • 2,268 View
  • 185 Download
  • 1 Web of Science
  • 1 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Glucagon-like peptide-1 receptor agonist (GLP-1RA), which is a therapeutic agent for the treatment of type 2 diabetes mellitus, has a beneficial effect on the cardiovascular system.
To examine the protective effects of GLP-1RAs on proliferation and migration of vascular smooth muscle cells (VSMCs), A-10 cells exposed to angiotensin II (Ang II) were treated with either exendin-4, liraglutide, or dulaglutide. To examine the effects of GLP-1RAs on vascular calcification, cells exposed to high concentration of inorganic phosphate (Pi) were treated with exendin-4, liraglutide, or dulaglutide.
Ang II increased proliferation and migration of VSMCs, gene expression levels of Ang II receptors AT1 and AT2, proliferation marker of proliferation Ki-67 (Mki-67), proliferating cell nuclear antigen (Pcna), and cyclin D1 (Ccnd1), and the protein expression levels of phospho-extracellular signal-regulated kinase (p-Erk), phospho-c-JUN N-terminal kinase (p-JNK), and phospho-phosphatidylinositol 3-kinase (p-Pi3k). Exendin-4, liraglutide, and dulaglutide significantly decreased the proliferation and migration of VSMCs, the gene expression levels of Pcna, and the protein expression levels of p-Erk and p-JNK in the Ang II-treated VSMCs. Erk inhibitor PD98059 and JNK inhibitor SP600125 decreased the protein expression levels of Pcna and Ccnd1 and proliferation of VSMCs. Inhibition of GLP-1R by siRNA reversed the reduction of the protein expression levels of p-Erk and p-JNK by exendin-4, liraglutide, and dulaglutide in the Ang II-treated VSMCs. Moreover, GLP-1 (9-36) amide also decreased the proliferation and migration of the Ang II-treated VSMCs. In addition, these GLP-1RAs decreased calcium deposition by inhibiting activating transcription factor 4 (Atf4) in Pi-treated VSMCs.
These data show that GLP-1RAs ameliorate aberrant proliferation and migration in VSMCs through both GLP-1Rdependent and independent pathways and inhibit Pi-induced vascular calcification.


Citations to this article as recorded by  
  • Incretin Hormone Secretion in Women with Polycystic Ovary Syndrome: Roles of Obesity, Insulin Sensitivity and Treatment with Metformin and GLP-1s
    Andrea Etrusco, Mislav Mikuš, Antonio D’Amato, Fabio Barra, Petar Planinić, Trpimir Goluža, Giovanni Buzzaccarini, Jelena Marušić, Mara Tešanović, Antonio Simone Laganà
    Biomedicines.2024; 12(3): 653.     CrossRef
The Role of Oxidative Stress in the Pathogenesis of Diabetic Vascular Complications
Shuji Sasaki, Toyoshi Inoguchi
Diabetes Metab J. 2012;36(4):255-261.   Published online August 20, 2012
  • 4,026 View
  • 64 Download
  • 60 Crossref
AbstractAbstract PDFPubReader   

Oxidative stress has been paid increasing attention to as an important causative factor for diabetic vascular complications. Among possible various sources, accumulating evidence has indicated that NAD(P)H oxidase may be the most important source for reactive oxygen species production in diabetic vascular tissues. The mechanisms underlying activation and up-regulation of NAD(P)H oxidase has been supposed to be mediated by high glucose-induced protein kinase C (PKC) activation. In this review article, activation of local renin-angiotensin II system induced by chymase activation is also shown to amplify such a PKC-dependent activation of NAD(P)H oxidase. Additionally, human evidence showing the beneficial effect of antioxidants on diabetic vascular complications. Bilirubin has been recognized as a strong endogenous antioxidant. Here markedly lower prevalence of vascular complications is shown in diabetic patients with Gilbert syndrome, a congenital hyperbilirubinemia, as well as reduced markers of oxidative stress and inflammation. Lastly, statin, angiotensin II receptor blocker, chymase inhibitor, bilirubin and biliverdin, PKC β isoform inhibitor, and glucagon-like peptide-1 analog, are shown to serve as antioxidants and have some beneficial effect on diabetic vascular complications, via inhibiting PKC-NAD(P)H oxidase activation, supporting the notion that this mechanism may be an effective therapeutic target for preventing diabetic vascular complications.


Citations to this article as recorded by  
  • The effects of whey protein on anthropometric parameters, resting energy expenditure, oxidative stress, and appetite in overweight/obese women with type 2 diabetes mellitus: A randomized placebo controlled clinical trial
    Maryam Nouri, Bahram Pourghassem Gargari, Zahra Ghasempour, Vahideh Sadra, Mohammad Asghari Jafarabadi, Arvin Babaei, Pedram Tajfar, Ali Tarighat-Esfanjani
    International Journal of Diabetes in Developing Countries.2024; 44(1): 155.     CrossRef
  • Rhodanine-benzamides as potential hits for α-amylase enzyme inhibitors and radical (DPPH and ABTS) scavengers
    Samuel Attah Egu, Irfan Ali, Khalid Mohammed Khan, Sridevi Chigurupati, Urooj Qureshi, Uzma Salar, Zaheer Ul-Haq, Suliman A. Almahmoud, Shatha Ghazi Felemban, Mohsin Ali, Muhammad Taha
    Molecular Diversity.2024;[Epub]     CrossRef
  • Research Progress of FGF-21 and CVAI in Type 2 Diabetic Kidney Disease
    央宗 才巴
    Advances in Clinical Medicine.2023; 13(07): 12056.     CrossRef
  • Is Subcutaneous Rifamycin Application Superior to Saline Application in Hip Hemiarthroplasty?
    Malik Çelik, Nezih Ziroğlu, Alkan Bayrak
    Bakirkoy Tip Dergisi / Medical Journal of Bakirkoy.2023; 19(2): 186.     CrossRef
  • In pursuit of incorporation of markers of oxidative stress in traditional biochemical panels in clinical Chemistry: A risk assessment step in diagnosis and biotherapy
    John Ibhagbemien Anetor, Chukwuemelie Zedech Uche, Gloria Oiyahumen Anetor
    American Journal of Biopharmacy and Pharmaceutical Sciences.2022; 2: 1.     CrossRef
  • Pathophysiologic Mechanisms and Potential Biomarkers in Diabetic Kidney Disease
    Chan-Young Jung, Tae-Hyun Yoo
    Diabetes & Metabolism Journal.2022; 46(2): 181.     CrossRef
  • p38 MAPK Inhibitor (SB203580) and Metformin Reduces Aortic Protein Carbonyl and Inflammation in Non-obese Type 2 Diabetic Rats
    Nuttikarn Nokkaew, Podsawee Mongkolpathumrat, Ruttanapong Junsiri, Supawit Jindaluang, Nichagron Tualamun, Niya Manphatthanakan, Nareumon Saleesee, Marisa Intasang, Jantira Sanit, Punyanuch Adulyaritthikul, Kantapich Kongpol, Sarawut Kumphune, Nitirut Ner
    Indian Journal of Clinical Biochemistry.2021; 36(2): 228.     CrossRef
  • Resveratrol-Elicited PKC Inhibition Counteracts NOX-Mediated Endothelial to Mesenchymal Transition in Human Retinal Endothelial Cells Exposed to High Glucose
    Roberta Giordo, Gheyath K. Nasrallah, Anna Maria Posadino, Francesco Galimi, Giampiero Capobianco, Ali Hussein Eid, Gianfranco Pintus
    Antioxidants.2021; 10(2): 224.     CrossRef
    Ugiloy Yusufovna Yusupova, Nurmurod Sheralievich Ramazonov, Khairulla Mamadievich Bobakulov, Feruza Rustamovna Egamova, Vladimir Nikolaevich Syrov, Durbek Abdikhoshimovich Usmanov
    chemistry of plant raw material.2021; (1): 197.     CrossRef
  • Chronically Elevated Exogenous Glucose Elicits Antipodal Effects on the Proteome Signature of Differentiating Human iPSC-Derived Pancreatic Progenitors
    Luiza Ghila, Thomas Aga Legøy, Andreas Frøslev Mathisen, Shadab Abadpour, Joao A. Paulo, Hanne Scholz, Helge Ræder, Simona Chera
    International Journal of Molecular Sciences.2021; 22(7): 3698.     CrossRef
  • Effect of Type-2 Diabetes Mellitus in Retinopathy Patients on MDA, SOD Activity and its Correlation with HbA1c
    Yali Hou, Mei Lin, Xuan Qiu, Mingjuan He, Yu Zhang, Feifei Guo
    Brazilian Archives of Biology and Technology.2021;[Epub]     CrossRef
  • Ameliorative effects of Hydrolea zeylanica in streptozotocin-induced oxidative stress and metabolic changes in diabetic rats
    Sandeep Kumar Swain, Umesh Chandra Dash, Satish Kanhar, Atish Kumar Sahoo
    Journal of Ethnopharmacology.2020; 247: 112257.     CrossRef
  • Imbalance in the antioxidant defence system and pro-genotoxic status induced by high glucose concentrations: In vitro testing in human liver cells
    Mattia Acito, Desirée Bartolini, Maria Rachele Ceccarini, Carla Russo, Samuele Vannini, Luca Dominici, Michela Codini, Milena Villarini, Francesco Galli, Tommaso Beccari, Massimo Moretti
    Toxicology in Vitro.2020; 69: 105001.     CrossRef
  • Synthesis of sulpha drug based hydroxytriazene derivatives: Anti-diabetic, antioxidant, anti-inflammatory activity and their molecular docking studies
    Poonam Sharma, Varsha Dayma, Aparna Dwivedi, Prabhat K. Baroliya, I.P. Tripathi, Murugesan Vanangamudi, R.S. Chauhan, A.K. Goswami
    Bioorganic Chemistry.2020; 96: 103642.     CrossRef
  • Analysis of long non-coding RNA expression profiles in high-glucose treated vascular endothelial cells
    Erqin Xu, Xiaolei Hu, Xiaoli Li, Guoxi Jin, Langen Zhuang, Qiong Wang, Xiaoyan Pei
    BMC Endocrine Disorders.2020;[Epub]     CrossRef
  • Potent α-amylase inhibitors and radical (DPPH and ABTS) scavengers based on benzofuran-2-yl(phenyl)methanone derivatives: Syntheses, in vitro, kinetics, and in silico studies
    Irfan Ali, Rafaila Rafique, Khalid Mohammed Khan, Sridevi Chigurupati, Xingyue Ji, Abdul Wadood, Ashfaq Ur Rehman, Uzma Salar, Muhammad Shahid Iqbal, Muhammad Taha, Shahnaz Perveen, Basharat Ali
    Bioorganic Chemistry.2020; 104: 104238.     CrossRef
  • A review of fibroblast growth factor 21 in diabetic cardiomyopathy
    Xiang Zhang, Luo Yang, Xiongfeng Xu, Fengjuan Tang, Peng Yi, Bo Qiu, Yarong Hao
    Heart Failure Reviews.2019; 24(6): 1005.     CrossRef
  • Recent advances in the pathogenesis of microvascular complications in diabetes
    Sungmi Park, Hyeon-Ji Kang, Jae-Han Jeon, Min-Ji Kim, In-Kyu Lee
    Archives of Pharmacal Research.2019; 42(3): 252.     CrossRef
  • Metabolic syndrome status over 2 years predicts incident chronic kidney disease in mid-life adults: a 10-year prospective cohort study
    So Jin Lee, Hun Ju Lee, Hyun jeong Oh, Taehwa Go, Dae Ryong Kang, Jang Young Kim, Ji Hye Huh
    Scientific Reports.2018;[Epub]     CrossRef
  • Role of peroxisome proliferator–activated receptor-gamma activation on visfatin, advanced glycation end products, and renal oxidative stress in obesity-induced type 2 diabetes mellitus
    A Tabassum, T Mahboob
    Human & Experimental Toxicology.2018; 37(11): 1187.     CrossRef
  • Coffee consumption and reduced risk of developing type 2 diabetes: a systematic review with meta-analysis
    Mattias Carlström, Susanna C Larsson
    Nutrition Reviews.2018; 76(6): 395.     CrossRef
  • Liraglutide ameliorates early renal injury by the activation of renal FoxO1 in a type 2 diabetic kidney disease rat model
    Pin Chen, Xiaozhi Shi, Xiangjin Xu, Yiyang Lin, Zhulin Shao, Rongdan Wu, Lihong Huang
    Diabetes Research and Clinical Practice.2018; 137: 173.     CrossRef
  • Antioxidant effects of vitamins in type 2 diabetes: a meta-analysis of randomized controlled trials
    Maria E. Balbi, Fernanda S. Tonin, Antonio M. Mendes, Helena H. Borba, Astrid Wiens, Fernando Fernandez-Llimos, Roberto Pontarolo
    Diabetology & Metabolic Syndrome.2018;[Epub]     CrossRef
  • Gilbert syndrome in patients with type 1 diabetes-Prevalence, glycemic control, and microalbuminuria
    Sigal Singer, Nurit Pilpel, Orit Pinhas-Hamiel
    Pediatric Diabetes.2017; 18(8): 803.     CrossRef
  • Low serum bilirubin level predicts the development of chronic kidney disease in patients with type 2 diabetes mellitus
    Kang Hee Ahn, Sang Soo Kim, Won Jin Kim, Jong Ho Kim, Yun Jeong Nam, Su Bin Park, Yun Kyung Jeon, Bo Hyun Kim, In Joo Kim, Yong Ki Kim
    The Korean Journal of Internal Medicine.2017; 32(5): 875.     CrossRef
  • Tiron ameliorates high glucose‐induced cardiac myocyte apoptosis by PKCδ‐dependent inhibition of osteopontin
    Ping Jiang, Deling Zhang, Hong Qiu, Xianqi Yi, Yemin Zhang, Yingkang Cao, Bo Zhao, Zhongyuan Xia, Changhua Wang
    Clinical and Experimental Pharmacology and Physiology.2017; 44(7): 760.     CrossRef
  • Protective effects of 6-Gingerol on vascular endothelial cell injury induced by high glucose via activation of PI3K-AKT-eNOS pathway in human umbilical vein endothelial cells
    Dan Liu, Mengqing Wu, Yi Lu, Tao Xian, Yupeng Wang, Bowei Huang, Guohua Zeng, Qiren Huang
    Biomedicine & Pharmacotherapy.2017; 93: 788.     CrossRef
  • Adenosine signaling in diabetes mellitus and associated cardiovascular and renal complications
    Maria Peleli, Mattias Carlstrom
    Molecular Aspects of Medicine.2017; 55: 62.     CrossRef
  • Diabetes and increased lipid peroxidation are associated with systemic inflammation even in well-controlled patients
    Alliny de Souza Bastos, Dana T. Graves, Ana Paula de Melo Loureiro, Carlos Rossa Júnior, Sâmia Cruz Tfaile Corbi, Fausto Frizzera, Raquel Mantuaneli Scarel-Caminaga, Niels Olsen Câmara, Oelisoa M. Andriankaja, Meire I. Hiyane, Silvana Regina Perez Orrico
    Journal of Diabetes and its Complications.2016; 30(8): 1593.     CrossRef
  • Agkistrodon acutus-purified protein C activator protects human umbilical vein endothelial cells against H2O2-induced apoptosis
    Shu Li, Yun Hong, Xin Jin, Xianwei Li, Entao Sun, Genbao Zhang, Linming Lu, Liuwang Nie
    Pharmaceutical Biology.2016; 54(12): 3285.     CrossRef
  • The impact of mast cells on cardiovascular diseases
    Eva Kritikou, Johan Kuiper, Petri T. Kovanen, Ilze Bot
    European Journal of Pharmacology.2016; 778: 103.     CrossRef
  • Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obesity
    Weiping Sun, Chunping Zeng, Lizhen Liao, Juan Chen, Ying Wang
    Current Medical Research and Opinion.2016; 32(8): 1389.     CrossRef
  • Mechanisms for the cardiovascular effects of glucagon-like peptide-1
    H. Poudyal
    Acta Physiologica.2016; 216(3): 277.     CrossRef
  • Integrated scientific data bases review on asulacrine and associated toxicity
    Attia Afzal, Muhammad Sarfraz, Zimei Wu, Guangji Wang, Jianguo Sun
    Critical Reviews in Oncology/Hematology.2016; 104: 78.     CrossRef
  • Impact of Diabetes and Defective Thyroid Ontogenesis on Audition
    Luciene da Cruz Fernandes
    Journal of Diabetes, Metabolic Disorders & Control.2016;[Epub]     CrossRef
  • Serum Total Bilirubin Levels Provide Additive Risk Information over the Framingham Risk Score for Identifying Asymptomatic Diabetic Patients at Higher Risk for Coronary Artery Stenosis
    Jaechan Leem, Eun Hee Koh, Jung Eun Jang, Chang-Yun Woo, Jin Sun Oh, Min Jung Lee, Joon-Won Kang, Tae-Hwan Lim, Chang Hee Jung, Woo Je Lee, Joong-Yeol Park, Ki-Up Lee
    Diabetes & Metabolism Journal.2015; 39(5): 414.     CrossRef
  • Clinical implications of carotid artery intima media thickness assessment on cardiovascular risk stratification in hyperlipidemic Korean adults with diabetes: the ALTO study
    Eun-Gyoung Hong, Jung Hun Ohn, Seong Jin Lee, Hyuk Sang Kwon, Sin Gon Kim, Dong Jun Kim, Dong Sun Kim
    BMC Cardiovascular Disorders.2015;[Epub]     CrossRef
  • Undiagnosed diabetes is prevalent in younger adults and associated with a higher risk cardiometabolic profile compared to diagnosed diabetes
    Yong-ho Lee, Ehrin J. Armstrong, Gyuri Kim, Jaewon Oh, Seok-Min Kang, Byung-Wan Lee, Chul Woo Ahn, Bong Soo Cha, Hyun Chul Lee, Christos S. Mantzoros, Eun Seok Kang
    American Heart Journal.2015; 170(4): 760.     CrossRef
  • Common Polymorphisms in Antioxidant Genes are Associated with Diabetic Nephropathy in Type 2 Diabetes Patients
    Jasna Klen, Katja Goričar, Andrej Janež, Vita Dolžan
    Personalized Medicine.2015; 12(3): 187.     CrossRef
  • Increased endogenous serotonin level in diabetic conditions may lead to cardiac valvulopathy via reactive oxygen species regulation
    Tahir Ali, Hina Waheed, Farhat Shaheen, Madiha Mahmud, Qamar Javed, Iram Murtaza
    Biologia.2015; 70(2): 273.     CrossRef
  • Antioxidant Effects of Statins in the Management of Cardiometabolic Disorders
    Soo Lim, Philip Barter
    Journal of Atherosclerosis and Thrombosis.2014; 21(10): 997.     CrossRef
  • Evidence-Based Practice Use of Incretin-Based Therapy in the Natural History of Diabetes
    Stanley Schwartz
    Postgraduate Medicine.2014; 126(3): 66.     CrossRef
  • Low serum bilirubin concentration is a novel risk factor for the development of albuminuria in patients with type 2 diabetes
    Hiroshi Okada, Michiaki Fukui, Muhei Tanaka, Shinobu Matsumoto, Kanae Kobayashi, Hiroya Iwase, Kiichiro Tomiyasu, Koji Nakano, Goji Hasegawa, Naoto Nakamura
    Metabolism.2014; 63(3): 409.     CrossRef
  • Serum total bilirubin levels and prevalence of diabetic retinopathy in a Chinese population (中国人群血清总胆红素水平与糖尿病视网膜病变相关性的研究)
    Syeda Sadia Najam, Jichao Sun, Jie Zhang, Min Xu, Jieli Lu, Kan Sun, Mian Li, Tiange Wang, Yufang Bi, Guang Ning
    Journal of Diabetes.2014; 6(3): 221.     CrossRef
  • Roles of oxidative stress, adiponectin, and nuclear hormone receptors in obesity-associated insulin resistance and cardiovascular risk
    Morihiro Matsuda, Iichiro Shimomura
    Hormone Molecular Biology and Clinical Investigation.2014;[Epub]     CrossRef
  • Unilateral injection of Aβ25–35 in the hippocampus reduces the number of dendritic spines in hyperglycemic rats
    Zayda Lazcano, Oscar Solis, María Elena Bringas, Daniel Limón, Alfonso Diaz, Blanca Espinosa, Isabel García‐Peláez, Gonzalo Flores, Jorge Guevara
    Synapse.2014; 68(12): 585.     CrossRef
  • Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications
    Vaibhav B. Patel, Nirmal Parajuli, Gavin Y. Oudit
    Clinical Science.2014; 126(7): 471.     CrossRef
  • Pathogenesis of Chronic Hyperglycemia: From Reductive Stress to Oxidative Stress
    Liang-Jun Yan
    Journal of Diabetes Research.2014; 2014: 1.     CrossRef
  • Daily intake of vitamin D‐ or calcium‐vitamin D‐fortified Persian yogurt drink (doogh) attenuates diabetes‐induced oxidative stress: evidence for antioxidative properties of vitamin D
    B. Nikooyeh, T. R. Neyestani, N. Tayebinejad, H. Alavi‐Majd, N. Shariatzadeh, A. Kalayi, M. Zahedirad, S. Heravifard, S. Salekzamani
    Journal of Human Nutrition and Dietetics.2014; 27(s2): 276.     CrossRef
  • Roles of adiponectin and oxidative stress in obesity-associated metabolic and cardiovascular diseases
    Morihiro Matsuda, Iichiro Shimomura
    Reviews in Endocrine and Metabolic Disorders.2014; 15(1): 1.     CrossRef
  • PKCδ-dependent Activation of the Ubiquitin Proteasome System is Responsible for High Glucose-induced Human Breast Cancer MCF-7 Cell Proliferation, Migration and Invasion
    Shan Zhu, Feng Yao, Wen-Huan Li, Jin-Nan Wan, Yi-Min Zhang, Zhao Tang, Shahzad Khan, Chang-Hua Wang, Sheng-Rong Sun
    Asian Pacific Journal of Cancer Prevention.2013; 14(10): 5687.     CrossRef
  • Increased oxidative stress in obesity: Implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer
    Morihiro Matsuda, Iichiro Shimomura
    Obesity Research & Clinical Practice.2013; 7(5): e330.     CrossRef
  • Hydrogen Sulfide Suppresses High Glucose–Induced Expression of Intercellular Adhesion Molecule-1 in Endothelial Cells
    Qingbo Guan, Xiaolei Wang, Ling Gao, Jicui Chen, Yuantao Liu, Chunxiao Yu, Nan Zhang, Xu Zhang, Jiajun Zhao
    Journal of Cardiovascular Pharmacology.2013; 62(3): 278.     CrossRef
  • Clinical Marker of Platelet Hyperreactivity in Diabetes Mellitus
    Jin Hwa Kim, Hak Yeon Bae, Sang Yong Kim
    Diabetes & Metabolism Journal.2013; 37(6): 423.     CrossRef
  • Glucose initially inhibits and later stimulates blood ROS generation
    Thomas Stief
    Journal of Diabetes Mellitus.2013; 03(01): 15.     CrossRef
  • Oxidative Stress in Cardiovascular Diseases and Obesity: Role of p66Shc and Protein Kinase C
    Elena De Marchi, Federica Baldassari, Angela Bononi, Mariusz R. Wieckowski, Paolo Pinton
    Oxidative Medicine and Cellular Longevity.2013; 2013: 1.     CrossRef
  • Toxicological and pharmacological concerns on oxidative stress and related diseases
    Soodabeh Saeidnia, Mohammad Abdollahi
    Toxicology and Applied Pharmacology.2013; 273(3): 442.     CrossRef
  • Comparison of antioxidant, α-glucosidase inhibition and anti-inflammatory activities of the leaf and root extracts ofSmilax chinaL.
    Kyoung Kon Kim, Yun Hwan Kang, Dae Jung Kim, Tae Woo Kim, Myeon Choe
    Journal of Nutrition and Health.2013; 46(4): 315.     CrossRef
  • Correlation between blood glucose fluctuations and activation of oxidative stress in type 1 diabetic children during the acute metabolic disturbance period
    Di WU, Chun-xiu GONG, Xi MENG, Qiu-lan YANG
    Chinese Medical Journal.2013; 126(21): 4019.     CrossRef
  • Oxidative stress and its complications in human health
    Guniz M. Koksal
    Advances in Bioscience and Biotechnology.2012; 03(08): 1113.     CrossRef
Original Articles
Angiotensin II Inhibits Insulin Binding to Endothelial Cells
Su-Jin Oh, Won-Chul Ha, Jee-In Lee, Tae-Seo Sohn, Ji-Hyun Kim, Jung-Min Lee, Sang-Ah Chang, Oak-Kee Hong, Hyun-Shik Son
Diabetes Metab J. 2011;35(3):243-247.   Published online June 30, 2011
  • 3,959 View
  • 24 Download
  • 6 Crossref
AbstractAbstract PDFPubReader   

Insulin-mediated glucose uptake in insulin target tissues is correlated with interstitial insulin concentration, rather than plasma insulin concentration. Therefore, insulin delivery to the interstitium of target tissues is very important, and the endothelium may also play an important role in the development of insulin resistance.


After treating bovine aortic endothelial cells with angiotensin II (ATII), we observed the changes in insulin binding capacity and the amounts of insulin receptor (IR) on the cell membranes and in the cytosol.


After treatment of 10-7M ATII, insulin binding was decreased progressively, up to 60% at 60 minutes (P<0.05). ATII receptor blocker (eprosartan) dose dependently improved the insulin binding capacity which was reduced by ATII (P<0.05). At 200 µM, eprosartan fully restored insulin binding capacity, althogh it resulted in only a 20% to 30% restoration at the therapeutic concentration. ATII did not affect the total amount of IR, but it did reduce the amount of IR on the plasma membrane and increased that in the cytosol.


ATII decreased the insulin binding capacity of the tested cells. ATII did not affect the total amount of IR but did decrease the amount of IR on the plasma membrane. Our data indicate that ATII decreases insulin binding by translocating IR from the plasma membrane to the cytosol. The binding of insulin to IR is important for insulin-induced vasodilation and transendothelial insulin transport. Therefore, ATII may cause insulin resistance through this endothelium-based mechanism.


Citations to this article as recorded by  
  • Acute, local infusion of angiotensin II impairs microvascular and metabolic insulin sensitivity in skeletal muscle
    Dino Premilovac, Emily Attrill, Stephen Rattigan, Stephen M Richards, Jeonga Kim, Michelle A Keske
    Cardiovascular Research.2019; 115(3): 590.     CrossRef
  • Angiotensin II type 2 receptor inhibits expression and function of insulin receptor in rat renal proximal tubule cells
    Yang Yang, Caiyu Chen, Chunjiang Fu, Zaicheng Xu, Cong Lan, Yongchun Zeng, Zhi Chen, Pedro A. Jose, Ye Zhang, Chunyu Zeng
    Journal of the American Society of Hypertension.2018; 12(2): 135.     CrossRef
  • Endothelial function, its relation to arterial hypertension and the possibility of its modulation
    Vladislav Biel, Jan Novák, Luděk Pluháček, Jiří Špác
    Vnitřní lékařství.2018; 64(7-8): 762.     CrossRef
  • Evidence to Consider Angiotensin II Receptor Blockers for the Treatment of Early Alzheimer’s Disease
    Juan M. Saavedra
    Cellular and Molecular Neurobiology.2016; 36(2): 259.     CrossRef
  • Ameliorative effect of eprosartan on high-fat diet/streptozotocin-induced early diabetic nephropathy in rats
    Mohamed A. Morsy, Gehan H. Heeba, Magda E. Mahmoud
    European Journal of Pharmacology.2015; 750: 90.     CrossRef
  • Metabolic actions of angiotensin II and insulin: A microvascular endothelial balancing act
    Ranganath Muniyappa, Sahzene Yavuz
    Molecular and Cellular Endocrinology.2013; 378(1-2): 59.     CrossRef
Effect of Peroxisome Proliferator Activated Receptor-gamma Agonist, Angiotensin II Receptor Blocker and alpha-lipoic Acid on Renal VEGF Expression in Diabetic Nephropathy.
Jang Hyun Koh, Yeon Lee, Mi Jin Kim, Young Goo Shin, Eun Young Lee, Choon Hee Chung
Korean Diabetes J. 2004;28(5):367-376.   Published online October 1, 2004
  • 1,104 View
  • 20 Download
AbstractAbstract PDF
Diabetic nephropathy is one of the most serious complications in diabetes mellitus, and it is the leading cause of end stage renal disease. It has been reported that angiotensin converting enzyme inhibitor (ACEi) reduces the vascular endothelial growth factor (VEGF) expression, and so it plays an important role in reducing the renal damage. Peroxisome proliferator activated receptor-gamma (PPAR-gamma) agonist is known to reduce insulin resistance in type 2 diabetic patients. In the previous study, PPAR-gamma agonist was shown to lower VEGF expression in the retina, but it increased the plasma VEGF level. Alpha-lipoic acid (alpha-LA), which is an antioxidant, lowers the increased level of VEGF in retina as well. The precise role of PPAR-gamma agonist and alpha-LA on renal VEGF expression in diabetic nephropathy is still uncertain. We studied the effect of PPAR-gamma agonist, angiotensin II receptor blocker (ATIIRB) and alpha-LA on the renal VEGF expression in diabetic rats. METHODS: We used 60 Sprague-Dawley male rats, those were 8 weeks old and weighted about 300 g each as the study subjects. Among them, 48 rats were chosen and injected with streptozotocin (70 mg/kg) into peritoneal cavity to induce diabetes mellitus. The rast were than divided into 5 groups. Group I was a normal control group (n=12), group II was diabetic control group (n=12), group III was diabetic group that was given with PPAR-gamma agonist (n=12), group IV was the diabetic group that was given ATIIRB (n=12), and group V was the diabetic rats that were given alpha-LA (n=12). We measured their body weight, blood glucose levels, 24 hour urine protein and albumin levels at the baseline, the 8th and the 16th weeks of the experiment. On the 16th weeks of our experiment we extracted the kidneys to measure the glomerular volume, the optical density of the VEGF staining and VEGF mRNA expression. RESULTS: At the beginning of the study, the 5 groups all showed similar 24 hour urine albumin levels. At the 8th week, group II showed an increased urine albumin level of 143.4 +/- 117.2 mg/day; this was greater than that of group IV (60.7+/-30.6 mg/day) (p<0.05). The glomerular volume and optical densities of VEGF expression were significantly reduced in group III, IV and V compared to group II. For group IV and V, the renal VEGF mRNA expression was significantly lower than that of group II, but group III showed no significant difference. from group II. CONCLUSION: Angiotensin II receptor blocker delayed the progression of diabetic nephropathy. PPAR-gamma agonist and alpha-lipoic acid did not have any protective effect against the progression of diabetic nephropathy in spite of the decreased VEGF expression noted in this study.
Effect of Angiotensin II Receptor Blockade on VEGF Expression in Diabetic Nephropathy.
Myoungsook Shim, Mijin Kim, Munkyu Kim, Hyunjin Chang, Younggoo Shin, Junam Kim, Jaeman Song, Hosuk Kang, Eunyoung Lee, Kihak Song, Choonhee Chung
Korean Diabetes J. 2003;27(2):106-114.   Published online April 1, 2003
  • 1,005 View
  • 17 Download
AbstractAbstract PDF
Diabetic nephropathy is one of the most serious complications of diabetes, and is the leading cause of chronic renal failure. Vascular endothelial growth factor (VEGF) plays an important role in the pathophysiology of diabetic retinopathy, which can be blocked by ACE inhibitors, but its precise role in diabetic nephropathy is uncertain. METHODS: 32 eight week-old Sprague-Dawley male rats were prepared, of which 16 were chosen for injection with streptozotocin (60 mg/kg) into the peritoneal cavity, with the goal of inducing diabetes. One week later, the peripheral blood sugar, taken from the tail vein was checked. A glucose level exceeding 200 mg/dL was taken as evidence of diabetes. The rats were divided into 4 groups of 8. Group I served as a control. Group II was treated with angiotensin II receptor blockade (L-158,809, 5 mg/kg/day, in drinking water). Group III consisted of diabetic rats and group IV diabetic rats treated with the same angiotensin II receptor blockade (L-158,809). At the beginning of the experiment and on 8th and 12th weeks, 24-hour urine protein and body weight checks were performed. At the end of the study, I extracted kidney and the glomerular volumes and optical densities of the VEGF expression in the glomeruli compared. RESULTS: The basal characteristics were initially the same. However, on weeks 8 and 12 the amount of 24-hour urine protein had increased in groups III and IV (p<0.05). By week 12, it was noticeably greater in group III than in group IV (p<0.05). The glomerular volume was also greater in groups III and IV (p<0.05). Optical density of the VEGF in the glomeruli had increased more in group III than in groups I, II and IV (p<0.05). CONCLUSION: VEGF plays a precise role in diabetic nephropathy, and angiotensin II receptor blockade can reduce diabetic nephropathy by suppressing the expression of VEGF.

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer